Abstract
<h3>Background</h3> Mutations in the tyrosine kinase domain of EGFR in non-small-cell lung cancer (NSCLC) are predictive of response to EGFR-targeted therapy in advanced stages of disease. This study aimed to determine the frequency of EGFR mutations in NSCLCs and to correlate their presence with clinical characteristics. <h3>Methods</h3> In this retrospective study, EGFR mutations in exons 18, 19, 20, and 21 in formalin-fixed paraffin-embedded biopsy specimens of consecutive NSCLC patients were assessed by real-time PCR. The study was conducted over a period of 5years from January 2009 to December 2013 in the Department of Medical Oncology in our institute. <h3>Findings</h3> EGFR mutations were detected in NSCLCs from 20 (25%) of 80 patients, being significantly more common in women (37.03%) than in men (18.8%) (odds ratio [OR] 0.39; 95% confidence interval [CI] 0.13–1.11; <i>p</i>=0.075) and in never smokers (42.85%) than in smokers and ex-smokers (11.11%) (OR 0.25, 95% CI 0.081–0.76; <i>p</i>=0.011). Mutations were more common in adenocarcinoma (32.07%) compared to non-adenocarcinoma NSCLCs (11.11%) (OR 3.7778; 95% CI 0.997–14.30; <i>p</i>=0.04). <h3>Interpretation</h3> In our patients with NSCLC, the EGFR mutation rate was similar to that in other Asian populations. EGFR mutations were significantly more common in female patients and in never smokers. Never smoking status of patients and adenocarcinoma histology were significant independent predictors for the presence of EGFR mutations.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call